Ozempic has ‘very rare’ sight loss side effect, EU drugs regulator finds - politico.eu
The EMA’s drug safety committee launched a review of medicines containing semaglutide — the active ingredient in Ozempic, Wegovy and Rybelsus — in January.
Search Group
Share To
Comments
About Screade
Screade® Inc. version 0a5de52, copyright 2016 - 2025
Blocked Users
Customize Dark Theme
Forgot your password?
Forgot your password?
Invite your friends
Please type emails of people you want to invite, we will send them invitation email on your behalf. Separate emails with comma if you want to invite multiple friends.
Comments